Working… Menu

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04354480
Recruitment Status : Completed
First Posted : April 21, 2020
Last Update Posted : February 17, 2021
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.

Brief Summary:
The main purpose of this study is to assess the safety and reactogenicity of the Ad26.preF based RSV vaccine administered intramuscularly as a single injection versus placebo in Japanese adults aged greater than equal to 60 years.

Condition or disease Intervention/treatment Phase
Healthy Biological: RSV Vaccine Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Single Vaccination of an Ad26.RSV.preF-based Regimen in Japanese Adults Aged 60 Years and Older
Actual Study Start Date : May 15, 2020
Actual Primary Completion Date : January 20, 2021
Actual Study Completion Date : January 20, 2021

Arm Intervention/treatment
Experimental: RSV Vaccine
Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
Biological: RSV Vaccine
Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.

Placebo Comparator: Placebo
Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
Other: Placebo
Participants will receive a single IM injection of matching placebo on Day 1.

Primary Outcome Measures :
  1. Number of Participants with Solicited Local Adverse Events (AEs) After Vaccination [ Time Frame: 7 days after vaccination (Day 1 to Day 8) ]
    Number of participants with solicited local AE's will be evaluated. Solicited local AEs (including erythema, swelling, and pain/tenderness at the study vaccine injection site) will be noted in the participant diary after 7 days of vaccination.

  2. Number of Participants with Solicited Systemic Adverse Events (AEs) After Vaccination [ Time Frame: 7 days after vaccination (Day 1 to Day 8) ]
    Number of participants with solicited systemic AEs will be evaluated. Solicited systemic AEs (fatigue, headache, myalgia, nausea and fever) will be noted in the participant diary after 7 days of vaccination.

  3. Number of Participants with Unsolicited AEs [ Time Frame: 28 days after vaccination (Day 1 to Day 29) ]
    Number of participants with unsolicited AEs will be evaluated. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary.

  4. Number of Participants with Serious Adverse Events (SAEs) [ Time Frame: First vaccination (Day 1) to the end of the study (up to Day 183) ]
    Number of participants with SAEs will be evaluated. A SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life threatening experience, is a congenital anomaly/birth defect, is suspected transmission of any infectious agent via a medicinal product, is medically important, and may jeopardize participant or may require medical or surgical intervention to prevent one of the outcomes listed above.

Secondary Outcome Measures :
  1. RSV Neutralization Assay [ Time Frame: Day 1 (pre-vaccination), Days 14, 28, and 182 (post-vaccination) ]
    Analysis of neutralizing antibodies to RSV A strain will be performed.

  2. RSV Fusion Protein (F-Protein) Binding Antibodies by Enzyme-linked Immunosorbent Assay (ELISA) [ Time Frame: Day 1 (pre-vaccination), Days 14, 28, and 182 (post-vaccination) ]
    Antibodies binding to RSV F-protein in pre-fusion and post-fusion forms will be assessed by ELISA.

  3. Interferon (IFN)-Gamma Enzyme-Linked Immunospot (ELISpot) Assay [ Time Frame: Day 1 (pre-vaccination) and Day 29 (post-vaccination) ]
    RSV F-specific cellular immune responses elicited by the different vaccine regimens.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Participant must be a Japanese participant whose parents and grandparents are Japanese as determined by the participant's verbal report
  • Before randomization, a woman must be: postmenopausal (A postmenopausal state is defined as no menses for 12 months without an alternative medical cause); not intending to conceive by any methods
  • A male participant must agree not to donate sperm for the purpose of reproduction for a minimum 28 days after receiving the dose of study vaccine
  • In the investigator's clinical judgment, participant must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms/signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs , and 12-lead electrocardiogram (ECG) performed at screening
  • From the time of vaccination through 3 months, participant agrees not to donate blood
  • Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study

Exclusion Criteria:

  • Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, end stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
  • Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively
  • Participant has had major psychiatric illness and/or drug or alcohol abuse which in the investigator's opinion would compromise the participant's safety and/or compliance with the study procedures
  • Participant has a history of chronic urticaria (recurrent hives), eczema and/or atopic dermatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04354480

Layout table for location information
Souseikai Hakata Clinic
Fukuoka, Japan, 812-0025
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Layout table for investigator information
Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial Janssen Pharmaceutical K.K.
Layout table for additonal information
Responsible Party: Janssen Pharmaceutical K.K. Identifier: NCT04354480    
Other Study ID Numbers: CR108768
VAC18193RSV1006 ( Other Identifier: Janssen Pharmaceutical K.K., Japan )
First Posted: April 21, 2020    Key Record Dates
Last Update Posted: February 17, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes